Foscarbidopa
A prodrug of carbidopa
| Foscarbidopa | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Foscarbidopa is a prodrug of carbidopa, which is used in the treatment of Parkinson's disease. It is designed to improve the bioavailability of carbidopa by enhancing its absorption and reducing its peripheral metabolism.
Mechanism of Action[edit | edit source]
Foscarbidopa is converted into carbidopa in the body. Carbidopa is a peripheral decarboxylase inhibitor that prevents the conversion of levodopa to dopamine outside the central nervous system. This allows more levodopa to reach the brain, where it can be converted to dopamine, thus alleviating the symptoms of Parkinson's disease.
Pharmacokinetics[edit | edit source]
Foscarbidopa is absorbed in the gastrointestinal tract and is rapidly converted to carbidopa. The conversion process involves enzymatic hydrolysis, which releases carbidopa into the bloodstream. This prodrug approach helps in overcoming the poor absorption and rapid metabolism associated with direct carbidopa administration.
Clinical Use[edit | edit source]
Foscarbidopa is primarily used in combination with levodopa for the management of Parkinson's disease. By inhibiting peripheral decarboxylation of levodopa, it enhances the availability of levodopa for conversion to dopamine in the brain, thereby improving motor function in patients.
Side Effects[edit | edit source]
The side effects of foscarbidopa are similar to those of carbidopa and may include nausea, dizziness, headache, and orthostatic hypotension. As with any medication affecting dopamine levels, there is a risk of dyskinesia and other movement disorders.
Development and Research[edit | edit source]
Foscarbidopa is part of ongoing research to improve the treatment of Parkinson's disease. Studies are focused on optimizing its formulation and delivery to maximize therapeutic benefits while minimizing side effects.
Related pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
